louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03654781: Impact of Periodontal Treatment on Gastric Helicobacter Pylori Eradication
Official title: Periodontal Tedavinin Helikobakter Pilori Eradikasyon ve Rekürrensine Katkısının İncelenmesi
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Helicobacter Pylori Infection
Keywords: periodontal treatment
Initial periodontal therapy
H. pylori
Lead sponsor: Ondokuz Mayıs University
Sponsor class: OTHER
First posted: 2018-08-31
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants with positive for both for H. pylori in gastric biopsy specimens and dental plaque samples by histologic examination with immunostaining and the rapid urease test (RUT), on gastric biopsy specimens obtained during gastrointestinal endoscopy were divided into 2 groups. Patients were allocated to one of the eradication regimens: triple therapy only or triple therapy combined with periodontal treatment. Each participant in both group received of a 10-day course of a proton pump inhibitor (Lansoprazole ) combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily). Meanwhile, combined treatment group further received periodontal treatment consisted of scaling or combined with root planing and oral hygiene instructions.
Primary purpose: TREATMENT

Brief summary: The efficacy of conventional systemic antibiotic therapy for eradication of gastric H. pylori has been seriously challenged by antibiotic resistance. Identification of alternative therapeutic strategies might help to overcome the limitation. The investigators' aim was to examine the effect of adjunct periodontal therapy, on gastric H. pylori eradication rate.


Eligibility criteria: Inclusion Criteria:

* tested positive for H. pylori both in gastric biopsy specimens and dental plaque samples

Exclusion Criteria:

The patients who had treatment with following medications within 6 months before the clinical protocol:

* had antibiotics
* had Proton pump inhibitor (PPI),
* had H2 blockers, and
* took bismuth derivatives
* had previous eradication therapy, or
* had previous periodontal therapy
* Edentulous patient
* Diabetic patients
* pregnant patients

Primary outcomes:
measure: eradication rate of gastric H. pylori infection
timeFrame: 3 months
Secondary outcomes:
measure: oral H. pylori eradication
timeFrame: 3 months
measure: periodontal parameters (Probing depth)
timeFrame: 3 months
measure: Clinical Attachment level
timeFrame: 3 months
measure: OHI (Oral Hygiene Index)
timeFrame: 3 months
measure: Gingival Index
timeFrame: 3 months
measure: Plaque index
timeFrame: 3 months
measure: Bleeding on Probing
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06894381: Characteristics and Results of Patients Treated by Therapeutic Intensification
Official title: Characteristics and Results of Patients Treated by Therapeutic Intensification Followed by Autograft of Peripheral Stem Cells and Admitted to Intensive Care and Intensive Care: Single-center Retrospective Analysis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Malignant Hemopathy
Keywords: Malignant hemopathy
allogeneic
stem cell
transplantation
chemotherapy
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2025-03-25
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patient (≥18 years old) admitted to the Intensive Care Unit within thirty days following therapeutic intensification and autograft of peripheral stem cells for the treatment of a hematologic malignancy

Brief summary: Many studies have focused on patients treated with allogeneic peripheral stem cell transplantation; few studies have until now been carried out to describe the characteristics and results of autografted patients and to attempt to determine possible prognostic factors. However, it is estimated that nearly 5% of autograft patients require MIR care. The investigators therefore wish to conduct a retrospective study including patients treated by therapeutic intensification followed by autograft of hematopoietic stem cells and admitted to the MIR department of the Hautepierre hospital of the University Hospitals of Strasbourg (HUS) within thirty days following initiation of chemotherapy.


Eligibility criteria: Inclusion Criteria:

* Adult patient (≥18 years old)
* Gender indifferent
* Admitted to the Intensive Care Unit within thirty days following therapeutic intensification and autograft of peripheral stem cells for the treatment of a hematologic malignancy between 01/01/2013 and 12/31/2022

Exclusion Criteria:

- Subject having expressed his opposition to the reuse of his data for scientific research purposes

Primary outcomes:
measure: Retrospective description of the clinical and biological characteristics of patients having therapeutic intensification and autograft of peripheral stem cells for the treatment of hematological malignancy
timeFrame: Thirty days following therapeutic intensification and autograft of peripheral stem cells in treatment of a malignant hematological disease.
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Médecine Intensive - Réanimation - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT04399681: The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19
Official title: The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19 at Emergency Department
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: COVID
Pneumonia, Viral
Lead sponsor: Kanuni Sultan Suleyman Training and Research Hospital
Sponsor class: OTHER
First posted: 2020-05-22
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Novel Coronavirus 2019 Disease (COVID-19) mortality is highly associated with viral pneumonia and its complications. Accurate and prompt diagnosis shown to be effective to improve outcome by providing early treatment strategies. While chest X-ray (CXR) and computerized tomography (CT) are defined as gold standard, given the advantage of being an ionized radiation free, practical technique point of care ultrasound (POCUS) is also reported as a diagnostic tool for COVID-19. There are limited studies regarding the importance of POCUS in diagnosis and review of COVID-19. Therefore the aim of this study is to evaluate the utility of bedside lung ultrasound on diagnosis of COVID-19 for patients admitted to emergency department .

Detailed description: Novel Coronavirus 2019 Disease (COVID-19) mortality is highly associated with viral pneumonia and its complications. Accurate and prompt diagnosis shown to be effective to improve outcome by providing early treatment strategies. While chest X-ray (CXR) and computerized tomography (CT) are defined as gold standard, given the advantage of being an ionized radiation free, practical technique point of care ultrasound (POCUS) is also reported as a diagnostic tool for COVID-19. There are limited studies regarding the importance of POCUS in diagnosis and review of COVID-19. Therefore the aim of this study is to evaluate the utility of bedside lung ultrasound on diagnosis of COVID-19 for patients admitted to emergency department .

Eligibility criteria: Inclusion Criteria:

* All patients with an informed consent
* Admission to emergency department with symptoms or signs of COVID-19

Exclusion Criteria:

* Absence of informed consent
* Patients under age of 18
* Presence of acute coronary syndrome
* Presence of chronic lung disease
* Pregnancy
* Presence of trauma
* Patients with a diagnosis of malignancy

Primary outcomes:
measure: Presence of viral pneumonia caused by COVID 19
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Kanuni Sultan Suleyman Training and Research Hospital
Study officials:
References:
Clinical trial NCT05615181: Evaluation of the French Translation of Gothenburg Trismus Questionnaire (GTQ)
Official title: Evaluation of the French Translation of Gothenburg Trismus Questionnaire (GTQ)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Trismus
Keywords: trismus
Patient reported outcomes
u Gothenburg Trismus Questionnaire
Lead sponsor: Centre Hospitalier de Valence
Sponsor class: OTHER
Collaborators: name: Göteborg University
First posted: 2022-11-14
Enrollment: 310
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient treated for trismus

Brief summary: A monocentric Study to evaluate the french translation of Gothenburg Trismus Questionnaire (GTQ).

Detailed description: Trismus is defined as a limitation in the mouth/jaw-opening ability due to a reduced mandible mobility. Trismus can occur from benign jaw related conditions, often referred to as temporomandibular disorders (TMD). It can also result from local or metastatic tumor growth of head and neck (H\&N) tumors, and more importantly, as a debilitating side-effect to H\&N oncology treatment, especially radiotherapy

The Gothenburg Trismus Questionnaire (GTQ) is a Patient Reported Outcome, validated in English, portuguese and sweden language.

The aim of this study is to develop a new tool in french language and to evaluate the specific impact of trismus on quality of life .

Eligibility criteria: * Inclusion Criteria:

  * Patient treated for trismus
  * Age ≥ 18 years old
  * Read, write and understand the French language
* Exclusion Criteria:

  * Patient under guardianship, deprived of liberty, safeguard of justice
  * Refusal to participate in research

Primary outcomes:
measure: Gothenburg Trismus Questionnaire (GTQ)
timeFrame: once at inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Valence
country: France
facility: Ch Valence
state: Drome
Study officials:
References:
Clinical trial NCT06599281: The Importance of Physiotherapy After Separation Surgery in Pygopagus Conjoined Twins
Official title: The Importance of Physiotherapy After Separation Surgery in Pygopagus Conjoined Twins
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pygopagus Conjoined Twins
Separation Surgery
Pediatric Physiotherapy
Keywords: conjoined twins
pygopagus
physiotherapy
gross motor development
neurodevelopment
Lead sponsor: Acıbadem Atunizade Hospital
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 4
Sex: ALL
Minimum age (years): 0
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Motor function delays are observed in pygopagus conjoined twins due to limited movement experience and deficits in proprioceptive sense. This study aimed to evaluate the neuromotor development of conjoined twins who acquired independent bodies, lives, and movements as a result of separation surgery, and to examine the effect of postoperative physiotherapy intervention on gross motor function.

Detailed description: The study included two cases of pygopagus conjoined twins who applied for separation surgery at Acıbadem Altunizade Hospital between 2021 and 2022. The twins were 9 months and 21 days old (A1-A2) and 23 months and 11 days old (B1-B2). After separation surgery, a conventional physiotherapy program was administered regularly for 3 months, 6 days a week, with two sessions per day, each lasting 45 minutes. The Bayley-III Developmental Screening Test (DST) was used to evaluate neuromotor development, while the Alberta Infant Motor Scale (AIMS) and the Gross Motor Function Measure-88 (GMFM-88) were used to assess gross motor development. Evaluations were performed preoperatively and at the 3rd postoperative month.

Eligibility criteria: Inclusion Criteria:

* Having a diagnosis of pygopagus conjoined twins
* Having normal vital signs after separation surgery

Exclusion Criteria:

* Having a diagnosis other than pygopagus conjoined twin
* Abnormal vital signs after separation surgery

Primary outcomes:
measure: Bayley-III Screening Test
timeFrame: 3 months
measure: Gross Motor Function Measure-88 (GMFM-88)
timeFrame: 3 months
measure: Alberta Infant Motor Scale (AIMS)
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Acıbadem Altunizade Hospital
Study officials:
affiliation: Acıbadem Atunizade Hospital
name: Gökçen EROL
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02227381: Action Medical Research
Official title: Using New Genetic Technology to Diagnose Neurodevelopmental Disorders
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Learning Disabilities
Lead sponsor: Manchester University NHS Foundation Trust
Sponsor class: OTHER_GOV
First posted: 2014-08-28
Enrollment: 119
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We will approach a cohort of patients with severe LD/seizures/behaviour problems who have presented to us in our genetic clinic for diagnosis over the past few years, but where the cause of their problems remains unknown. This will be our study population. In virtually all cases we will have performed routine diagnostic testing and will have stored DNA.

Brief summary: Learning disability affects 3% of the population. Severe types of learning disability are more likely to have an underlying genetic cause but diagnosis is difficult because many different genetic abnormalities may be involved. Obtaining a diagnosis is important so that patients can be managed appropriately and their families can be given accurate information.

We aim to use new types of genetic testing which will make it possible to screen for several different genetic abnormalities which cause learning disability at the same time, so improving the accuracy and speed of diagnosis in the group of patients with severe learning disability. We will focus particularly on patients where seizures and behavioural problems are also present.This will enable more patients to be diagnosed accurately, reduce the number of hospital appointments needed and ultimately be more cost- effective.


Eligibility criteria: Inclusion Criteria:

* Individuals with severe learning disability associated with either seizures, movement or behaviour problems who had previously undergone routine investigation but where no cause had been identified for their problems

Exclusion Criteria:

* Individuals with SLD where the cause is already known
* Individuals where informed consent cannot be obtained for participation

Primary outcomes:
measure: Genetic abnormality identified by microarray or Next Generation Sequencing
timeFrame: up to 6 months following consent
Secondary outcomes:
measure: Cost effectiveness vs normal care
timeFrame: By the end of the study (December 2014)
Other outcomes:
Locations:
city: Manchester
country: United Kingdom
facility: Central Manchester University Hospitals NHS Foundation Trust
Study officials:
affiliation: CMFT
name: Jill Clayton Smith, MB ChB FRCP MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00334581: Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
Official title: A Study of Irbesartan 150mg Verses 300mg in Chinese Hypertensive Patients With Diabetes and Microalbuminuria
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
Collaborators: name: Bristol-Myers Squibb
First posted: 2006-06-08
Enrollment: 192
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary objective:

* To determine if irbesartan 300mg is better than 150mg in protecting the kidneys in hypertensive patients with diabetes and microalbuminuria.

Secondary objectives:

* To determine how well irbesartan 300mg is tolerated versus 150mg
* To determine the percentage of patients reaching the blood pressure target of 130/80 mmHg


Eligibility criteria: Inclusion Criteria:

* Hypertensive patients, treated or untreated, with type 2 diabetes and urinary albumin excretion rate 20-200ug/min.
* Blood pressure of \< 180/110mmHg at baseline
* Normal serum creatinine

Exclusion Criteria:

* Type 1 diabetes
* Use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers in the 5 weeks before recruitment
* Pregnant or lactating women
* Severe hypertension
* Overt nephropathy
* Allergy to study drug

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: The difference of urinary albumin excretion rate change
timeFrame: at week 24
Secondary outcomes:
measure: Percentage of patients reaching target BP of 130/80mmHg
timeFrame: At week 24
measure: Adverse events
timeFrame: From the beginning to the end of the study
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: Bruno Jolain
role: STUDY_DIRECTOR
References:
Clinical trial NCT01290081: Enhanced Tuberculosis Case Detection Among Substitution Treatment Patients
Official title: Prevalence of Latent Tuberculosis and Enhanced Tuberculosis Case Detection Among Injecting Drug Users Receiving Methadone Substitution Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tuberculosis
Keywords: Tuberculosis
Injecting drug users
Case management
Lead sponsor: National Institute for Health Development, Estonia
Sponsor class: OTHER_GOV
Collaborators: name: LLC Corrigo
name: Ida-Viru Central Hospital, Department of Tuberculosis
First posted: 2011-02-04
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study was to determine the prevalence of latent tuberculosis infection among injecting drug users and to conduct randomized controlled trial to evaluate a case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program in Estonia.


Eligibility criteria: Inclusion Criteria:

* Participation in substitution treatment program,
* Age 18 years or more,
* Able to read and write in Estonian or Russian,
* Able to provide informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jõhvi
country: Estonia
facility: LLC Corrigo
state: Ida-Virumaa
Study officials:
References:
citation: Ruutel K, Loit HM, Sepp T, Kliiman K, McNutt LA, Uuskula A. Enhanced tuberculosis case detection among substitution treatment patients: a randomized controlled trial. BMC Res Notes. 2011 Jun 15;4:192. doi: 10.1186/1756-0500-4-192.
Clinical trial NCT04655781: Internal Limiting Membrane Peeling on Retinal Displacement
Official title: Displacement of the Retina After Idiopathic Macular Hole Surgery With Different Internal Limiting Membrane Peeling Patterns
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Internal Limiting Membrane Peeling
Keywords: Retinal displacement
Idiopathic macular hole
Internal limiting membrane peeling
Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
Sponsor class: OTHER
First posted: 2020-12-07
Enrollment: 20
Sex: ALL
Minimum age (years): 10
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate displacement of the retina after idiopathic macular hole surgery with different internal limiting membrane peeling patterns.

Detailed description: After being informed about the study and potential risks, all patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. All patients with idiopathic MH will be randomly allocated into two groups, N-T group or T-N group.

Eligibility criteria: Inclusion Criteria:

Eyes with idiopathic macular hole

Exclusion Criteria:

Eyes having re-do macular hole surgery, with high myopia, with proliferative vitreoretinopathy or with a retinal detachment combined with the MH, with other macular diseases, such as age-related macular degeneration.

Primary outcomes:
measure: T-OD
timeFrame: preoperation to postoperative 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: